| | 106861-44-3 Basic information More.. |
| Product Name: | Mivacurium chloride | | Synonyms: | MIVACURIUM CHLORIDE;rac Mivacurium Chloride;rac-BW-B 1090;rac-Mivacron;rel-(1R,1'R)-2,2'-[[(4E)-1,8-Dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]- isoquinolinium Chloride;[R-[R*,R*-(E)]]2,2'-(1,8-Dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl)bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium] dichloride;rac-BW-B 1090U;-1，2，3，4-Te．trahydro-2-(3-hydroxypropyl)-6，7-dimethoxy-2-methyl-1-(3，4，5-trimethoxy-benzyl)isoquinolinium chloride，(E)-4-octenedioate(2：1) | | CAS: | 106861-44-3 | | MF: | C58H80ClN2O14+ | | MW: | 1064.73 | | EINECS: | 643-006-4 | | Mol File: | 106861-44-3.mol |  |
Use
Mivacurium chloride,a mixture of three stereoisomers, is an intravenously
administered, short-acting skeletal muscle relaxant introduced as an adjunct to general
anesthesia. Structurally mivacurium chloride is closely related to doxacurium chloride
introduced in 1991 by Wellcome as a muscle relaxant. It is a nondepolarizing
neuromuscular blocking agent reportedly with a shorter duration of action and a more
rapid rate of spontaneous recovery than other nondepolarizing agents. In extensive
clinical trials mivacurium chloride was well tolerated with few side effects.
- Mivacurium dichloride
-
- US $40.00-91.00 / mg
- 2025-05-22
- CAS:106861-44-3
- Min. Order:
- Purity: 99.52%
- Supply Ability: 10g
- Mivacurium Chloride
-
- US $0.00-0.00 / mg
- 2024-04-11
- CAS:106861-44-3
- Min. Order: 10mg
- Purity: above 98%
- Supply Ability: 10g/month
- Mivacurium Dichloride
-
- US $200.00 / kg
- 2023-06-26
- CAS:106861-44-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg/Month
|
|
106861-44-3
Recommend Suppliers |
|